Integrated Investment Consultants LLC Has $3.03 Million Stock Holdings in Merck & Co., Inc. $MRK

Integrated Investment Consultants LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 53.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,816 shares of the company’s stock after acquiring an additional 10,087 shares during the quarter. Integrated Investment Consultants LLC’s holdings in Merck & Co., Inc. were worth $3,033,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. NWF Advisory Services Inc. raised its stake in Merck & Co., Inc. by 8.2% during the 4th quarter. NWF Advisory Services Inc. now owns 16,365 shares of the company’s stock worth $1,723,000 after buying an additional 1,247 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Merck & Co., Inc. during the fourth quarter worth about $389,000. Reflection Asset Management acquired a new position in Merck & Co., Inc. in the fourth quarter valued at about $401,000. CFO Capital Management LLC acquired a new position in Merck & Co., Inc. in the fourth quarter valued at about $615,000. Finally, Wick Capital Partners LLC bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $269,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

MRK opened at $114.04 on Friday. The business’s 50-day moving average price is $115.94 and its two-hundred day moving average price is $113.60. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $125.14. The company has a market capitalization of $281.65 billion, a price-to-earnings ratio of 32.12, a P/E/G ratio of 2.56 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be paid a $0.85 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 3.0%. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Analyst Ratings Changes

A number of research firms have recently commented on MRK. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. UBS Group increased their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, Citigroup started coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.